Labcorp poster describes a shared free-IgE assay for a head-to-head clinical study
Company / institutional announcement · Labcorp
Source published: · Event / reporting date: 2026-10-30
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Labcorp's CBF 2026 poster summary describes a unified serum free-IgE assay supporting comparison of two IgE-targeting drug candidates, including a marketed comparator. The team evaluated assay conditions that can disturb drug–IgE equilibrium and reports establishing a fit-for-purpose method. The public summary does not identify the therapies or provide numerical validation metrics; it is a conference report.
Why it may matter
Analysis: A common PD assay may improve interpretability across treatment arms by reducing method-driven differences, provided drug-related interference is adequately characterized.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections
Bioanalysis & Biomarkers Clinical Pharmacology & Model-Informed Development